Skip to Content
Merck
  • Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury.

Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury.

Biomaterials (2009-02-03)
Young-tae Kim, Jon-Michael Caldwell, Ravi V Bellamkonda
ABSTRACT

Systemic administration of a high-dose of Methylprednisolone (MP) can reduce neurological deficits after acute spinal cord injury (SCI). However, the use of high-dose MP in treating acute SCI is controversial due to significant dose related side effects and relatively modest improvements in neurological function. Here, using a rat model of SCI, we compare the efficacy of controlled, nanoparticle-enabled local delivery of MP to the injured spinal cord with systemic delivery of MP, and a single local injection of MP without nanoparticles. Based on histological and behavioral data, we report that local, sustained delivery of MP via nanoparticles is significantly more effective than systemic delivery. Relative to systemic delivery, MP-nanoparticle therapy significantly reduced lesion volume and improved behavioral outcomes. Nanoparticle-enabled delivery of MP presents an effective method for introducing MP locally after SCI and significantly enhances therapeutic effectiveness compared to bare MP administered either systemically or locally.

MATERIALS
Product Number
Brand
Product Description

USP
Methylprednisolone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Monoclonal Anti-Chondroitin Sulfate antibody produced in mouse, clone CS-56, ascites fluid
Methylprednisolone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
6α-Methylprednisolone, ≥98%